Stockpolly
Search
DMRA · NASDAQ · Biotechnology

Damora Therapeutics (DMRA)

Advances mutCALR-directed candidates for essential thrombocythemia and myelofibrosis.

$28.22
At close+0.08 (+0.28%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
5665433332023135
Research & development3322111111982426
333332222479
General & administrative000000222470
Operating income−6−6−6−5−4−3−3−3−3−202−31−35
−2−10−10−4000134
Interest income000000000134
Other non-operating income010104000−1−30
Income before tax−8−6−5−5−4−7−3−3−3−201−28−31
Income tax expense000000000000
Net income from continuing operations−8−6−5−5−4−7−3−3−3−201−28−31
Net income−8−6−5−5−4−7−3−3−3−201−28−31
EPS, basic−$7.50−$5.97−$5.05−$4.92−$3.39−$5.22−$1.92−$2.60−$2.36−$121.10−$0.81−$0.51
EPS, diluted−$7.50−$5.97−$5.05−$4.92−$3.39−$5.22−$1.92−$2.60−$2.36−$121.10−$0.81−$0.51
Weighted average shares, basic11111111123461
Weighted average shares, diluted11111111123461
EBITDA−5−6−5−5−4−7−3−3−3−201−28−35
Depreciation & amortization000000000000
EBIT−6−6−5−5−4−7−3−3−3−201−28−35